ketamine 80 mg/kg + xylazine 10 mg/kg and placed on warming pads prior to intranasal inoculation 20 with 1.5x10 6 A. fumigatus conidia. Animal inoculation was performed by slowly instilling a 30 l 21 droplet on both nares and the mice were allowed to inhale the inoculum in an upright position until 22 normal breathing resumed (16). After inoculation animals were returned to the warming pad and 23 Amphotericin B tissue concentrations. Determination of total AMB tissue concentrations 1 in infected lungs was performed by high-performance liquid chromatography using a modification 2 of a previously published assays (15, 20, 26) . Briefly, amphotericin B and a spiked internal 3 standard (1-amino-4-nitro-napthalene, ANNP) were isolated from tissue homogenates by 4 acetonitrile (ACN) precipitation of proteins followed by centrifugation. A 50 L aliquot of the 5 extracted supernatent was injected through a C18 guard column into a Nova-Pak C18 column 6 (3.9x150 mm, 4 M). AMB and ANNP (internal standard) were eluted at a flow rate of 1 mL per 7 minute with gradient program (ACN from 30 to 45% plus 2.5 mM EDTA from 70% to 55% in 8 8 minutes) and detected at 406 nm. The calibration curve was linear over a range of 0.25 to 10 g/g 9 in tissue. Mean inter-and intra-assay coefficients of variation over the range of the standard curve 10 were < 10%. The lower limit of accurately detectable AMB in tissue was 0.25 g/g. 11
Plasma beta glucan concentrations. Plasma beta-glucan (BG) concentrations in 12
infected animals treated with L-AMB or ABLC was determined using a commercially-available 13 assay according to the manufacturer's instructions (Fungitell; Associates of Cape Cod). Plasma 14 samples (5 L) were pretreated for 10 min at 37°C with an alkaline reagent (20 L; 0.125 M 15 KOH/0.6 M KCl) to inactivate serine proteases as well as inhibitors in mouse plasma and to 16 enhance the reactivity to activated factor G (28). After addition of the BG assay reagent, the 17 microtiter plate was inserted into a pre-incubated microplate spectrophotometer (Powerwave X 18 Select, Biotech Instruments, Winooski, VT) and a kinetic assay was run at absorbance 405 nm with 19 Statistical analysis. All data were expressed as means plus/minus standard errors of the 1 means (SEMs) and compared by Mann-Whitney test or one-way analysis of variance with Tukey's 2 post-test for multiple comparisons where appropriate. Differences were considered statistically 3 significant when P values were < 0.05. Total AMB tissue concentrations associated with inhibition 4 of A. fumigatus growth (stasis) or 1 log10 reduction in fungal burden at 24 hours were determined 5 by fitting a four-parameter logistic model (Hill equation) using computer curve-fitting software 6 (Prism 4, GraphPad Software, Inc, San Diego, CA, USA) to the experimental data. Goodness of fit 7
was assessed by R 2 and the standard error of the EC50 value. 8
RESULTS 9
Isolate susceptibility testing. Susceptibility testing performed in triplicate of the test 10 isolate AF 293, revealed an AMB MIC of 0.25 g/mL and a MFC of 2 g/mL. MIC and MFC results 11 were consistent throughout the study and with previously published in vitro studies that utilized the 12 same isolate (17). burden in excess of approximately 5x10 6 CE occurring among all three groups between 72-120 hrs 1 ( Figure 1A ) Therefore, experiments could not be completed until the 120 hr timepoint. AMB could 2 only be detected in lung tissue for ABLC-treated animals at 24 hours (mean 4.2 g/g + 1.77), but 3 was undetectable at later timepoints despite daily dosing and for all timepoints in L-AMB treated 4
animals. 5
Animals treated with L-AMB or ABLC at 5 mg/kg/day exhibited a significant reduction in 6 fungal burden vs. control animals at 72 hours (P<0.05). Clear differences in the pattern of fungal 7 burden reduction were observed between the two lipid AMB formulations with ABLC producing 8 immediate reductions in fungal burden by the first 24 hrs that was not seen with L-AMB until 72 9 hours ( Figure 1B tissue concentrations at subsequent timepoints were low or undetectable (< 0.25 g/g) in both the 9 ABLC and L-AMB treated animals ( Figure 3A) . A reduction in lung fungal burden was observed 10 with ABLC treated animals at 24 and 72 hrs ( Figure 1A) . Similar to the multi-dose 1mg/kg/day 11 studies, animal deaths occurred with both groups between 72-120 hours suggesting an increase in 12 fungal burden (data not shown on graph). 13
In the 10 mg/kg single dose studies, tissue concentrations of AMB persisted to 72 hours 14 but were undetectable at 120 hours ( Figure 3B ). Fungal clearance was equivalent between L-AMB 15 and ABLC, but reached a plateau at 24-72 hours failing to achieve the same decrease in fungal 16 burden reduction observed at 120 hrs in the multi-dose studies (9.44x10 3 vs. 6.43x10 4 A. fumigatusagreement with previous studies of experimental pulmonary aspergillosis (6, 22), we found that 1 treatment with L-AMB formulation was associated with effective, albeit delayed delivery of AMB in 2 the lung when dosed at 5 mg/kg/day that allowed fungal burden to increase in the first 24-48 hours 3 of treatment. In contrast, ABLC-treated animals had detectable concentrations of AMB in the lung 4 in the first 24 hours that surpassed MFC of the test isolate and produced evidence of fungal 5 clearance in the first 24-72 hours. By 120 hrs, however, no difference in fungal burden was 6 observed between the two formulations. Not surprisingly, these differences between these 7 formulations have not been confirmed in intravenous models of infection, where L-AMB is 8 immediately effective due to the high serum concentrations seen with intravenous dosing (10). 9
Moreover, when dosed at 10 mg/kg/day, both formulations achieved high concentrations in the 10 lung tissue in the first 24 hours and produced similar patterns of fungal clearance. The enhanced 11 rate of AMB distribution to the lung with 10mg/kg/day vs. 5 mg/kg/day may be a reflection of a 12 dose-dependent uptake or a high-dose, first-pass effect in the lung that has been reported with 13 other liposomal formulations (12, 13, 29). 14 Early clearance of A. fumigatus from the lung was associated with total AMB tissue 15 concentrations that surpassed the MFC of the infecting isolate. Using logistic regression, we 16 determined that AMB tissue concentrations of > 4 g/g were associated with significant reductions 17 cultures, was generally lower in ABLC-treated animals with a 20 mg/kg/day ABLC regimen 7 acheived the greatest reduction in fungal burden among all treatment groups (22). 8
One unexpected finding of our study was the pattern of decreasing tissue concentrations 9 over the course of the experiment despite daily dosing. Because a majority of animal studies that 10 have examined biodistribution of lipid AMB formulations in the lung examine only single doses or 11 single timepoints to assess plasma: tissue ratios of drug, we are unable to confirm if this 12 observation is indeed unique to our study (3, 6, 22) . Several factors could account for decreased 13 distribution of AMB during the course of repeated dosing in infected animals including saturation of 14 pathways involved in drug uptake in the lung and/or decreases in residual (lipid AMB containing) 15 phagocytic cell recruitment with decreasing fungal burden. Another possibility is that our method for 16 would expect a consistent pattern of decrease in all dosing regimens that was not clearly observed 18 between the two lipid AMB formulations (Figures 1B-1C ). Further studies with radiolabled AMB 19 would be required to address this issue. 20
When administered as single dosages of 5 of 10 mg/kg, neither L-AMB or ABLC were as 21 effective at reducing fungal burden as multiple daily dosing ( Figure 3A and 3B) . Indeed, AMB 22 tissue concentrations were undetectable by 120 hours and fungal clearance reached a plateau 23 after the first 24-48 hours. These data raise concerns whether dosing of lipid AMB formulations at 1 extended intervals (i.e. greater than 3-5 days) would be prudent for the treatment of established 2 IPA. However, higher-dose, infrequently-administered regimens may still be effective for lower 3 inocula infections or in the setting of prophylaxis. Additional studies will be required to confirm the 4 pharmacodynamics of extended interval dosing for the lipid AMB formulations. 5
Another novel aspect of this study is that we were able to demonstrate a good correlation 6 between A. fumigatus tissue fungal burden measured by quantitative real-time PCR and serum 7 concentrations of beta glucan (BG), including response to antifungal therapy. The BG test has 8 been reported to be a useful adjunctive diagnostic for aspergillosis in patients with acute 9 myelogenous leukemia, with a sensitivity of 69.9% and a specificity of 87.1% in patients with proven 10 infections when the 60 pg/mL cutoff value is used to define sample positivity (23). However, few 11 pre-clinical studies have compared serial measurements of BG concentrations in relation to direct 12 measurements of fungal burden in the lungs. We decided to use beta glucan as a surrogate marker 13 over galactomannan due to the greater dynamic range of the test; i.e. beta glucan is reported 14 quantitatively versus the semi-quantitative galactomannan test. While the majority of the 15 concentrations tested in this study fell below the 60 pg/mL, it is notable that samples that exceeded 16 this threshold in animals with progressing IPA or delayed response to antifungal therapy. Additional 17 pre-clinical and clinical studies are warranted to further explore the utility of serial BG analysis as a 18 surrogate for response to drug therapy. 19
In conclusion, our comparative analysis L-AMB or ABLC in the treatment of acute 20 experimental IPA revealed notable differences in the patterns of early AMB lung distribution and 21 fungal clearance when the formulations were dosed at 5 mg/kg/day, but no significant differences 22 in A. fumigatus clearance at 10 mg/kg/day. Differences in the speed of fungal clearance could be 23 largely attributed differences in the rate and extent of the respective formulations to deliver 1 "fungicidal" concentrations of AMB to the lung tissue. While the importance of these findings 2 remain to be determined in more slowly progressing forms of aspergillosis, our data suggest that 3 the biopharmaceutical differences between the lipid formulations could have potentially important 4 clinical implications for rapidly progressing fungal pneumonia (e.g., pulmonary zygomycosis). 5
Currently, studies are underway to confirm these results with more rapidly-invasive, less AMB 6 susceptible moulds. 
